|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 662.88 USD | -1.97% |
|
+6.31% | -14.12% |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 07-08 | MAIA Biotechnology Says Ateganosine Shows 90.5% Disease Control Rate in Phase 2 Expansion Trial | MT |
| Market Cap | 68.8B 60.25B 55.6B 51.38B 97.49B 6,573B 99.26B 666B 259B 3,223B 258B 253B 11,184B | P/E 2026 * |
17.5x | P/E 2027 * | 14.1x |
|---|---|---|---|---|---|
| Enterprise Value | 60.97B 53.39B 49.27B 45.53B 86.39B 5,825B 87.96B 591B 230B 2,856B 229B 224B 9,911B | EV / Sales 2026 * |
3.84x | EV / Sales 2027 * | 3.32x |
| Free-Float |
72.33% | Yield 2026 * |
0.58% | Yield 2027 * | 0.66% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -1.97% | ||
| 1 week | +6.31% | ||
| Current month | +6.31% | ||
| 1 month | +4.32% | ||
| 3 months | -12.81% | ||
| 6 months | -18.39% | ||
| Current year | -14.12% |
| 1 week | 625.7 |  | 677.92 |
| 1 month | 594.9 | | 677.92 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 31/12/2000 | |
| Chief Executive Officer | 73 | 07/01/1988 | |
| Director of Finance/CFO | 55 | 04/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 08/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 31/05/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 31/05/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-30 | Sell | Director | -100 | 0.0001% | ||
| 03-31 | Sell | Director | 100 | 0.0001% | ||
| 03-01 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.97% | +6.31% | +23.19% | -4.27% | 68.8B | |
| -2.01% | -5.08% | +46.38% | +217.46% | 55.21B | |
| -4.15% | +36.30% | +36.30% | +36.30% | 43.46B | |
| +0.27% | +8.33% | -49.87% | -53.43% | 41.18B | |
| -7.48% | +5.38% | +146.82% | -37.92% | 31.65B | |
| -2.60% | -7.27% | +53.97% | -27.16% | 30.37B | |
| -0.67% | +3.44% | +74.31% | +88.92% | 23.58B | |
| -1.15% | +8.29% | +4.42% | +184.96% | 19.33B | |
| -1.33% | +2.47% | +65.52% | +132.74% | 17.16B | |
| +0.54% | +5.17% | +80.07% | +363.77% | 15.27B | |
| Average | -1.07% | +3.83% | +48.11% | +90.14% | 34.6B | |
| Weighted average by Cap. | -1.38% | +3.59% | +40.90% | +65.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.87B 13.9B 12.83B 11.85B 22.49B 1,517B 22.9B 154B 59.84B 744B 59.61B 58.3B 2,580B | 17.55B 15.37B 14.18B 13.1B 24.87B 1,677B 25.32B 170B 66.15B 822B 65.89B 64.45B 2,853B |
| Net income | 4.06B 3.56B 3.28B 3.03B 5.76B 388B 5.86B 39.35B 15.31B 190B 15.25B 14.92B 660B | 5.11B 4.47B 4.13B 3.81B 7.23B 488B 7.37B 49.46B 19.24B 239B 19.17B 18.75B 830B |
| Net Debt | -7.83B -6.86B -6.33B -5.85B -11.1B -748B -11.3B -75.89B -29.53B -367B -29.42B -28.77B -1,273B | -10.5B -9.2B -8.49B -7.84B -14.88B -1,003B -15.15B -102B -39.58B -492B -39.43B -38.57B -1,707B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/26 | US$662.88 | -1.97% | 746,727 |
| 07/07/26 | US$676.23 | +4.07% | 918,937 |
| 06/07/26 | US$649.81 | -0.68% | 714,338 |
| 02/07/26 | US$654.27 | +4.73% | 1,071,604 |
| 01/07/26 | US$624.72 | +0.19% | 1,170,657 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
